Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 3,712	$ 2,841	$ 8,779	$ 9,021
General and administrative	2,651	1,385	6,377	3,110
Total operating expenses	6,363	4,226	15,156	12,131
Loss from operations	(6,363)	(4,226)	(15,156)	(12,131)
Other income:
Interest income	29	63	50	178
Total other income	29	63	50	178
Net loss	(6,334)	(4,163)	(15,106)	(11,953)
Comprehensive loss	$ (6,334)	$ (4,163)	$ (15,106)	$ (11,953)
Net loss per share attributable to common stockholders—basic and diluted	$ (0.49)	$ (19.20)	$ (2.13)	$ (63.33)
Weighted-average common shares outstanding—basic and diluted	12,924,682	220,902	7,133,967	192,433